Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
|Videos|May 12, 2017
Dr. Loeb on Active Surveillance for Prostate Cancer
Author(s)Stacy Loeb, MD
Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses active surveillance for patients with low-risk prostate cancer.
Advertisement
Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses active surveillance for patients with low-risk prostate cancer.
Active surveillance is a growing management option for patients with low-risk prostate cancer, states Loeb.
One of the concerns is that the risk classification for patients with prostate cancer is not completely accurate, explains Loeb. Genomic tests are being studied to confirm that patients are categorized appropriately.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
Calculating the Real Cost of False Positive Findings in Cancer Screening
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
5